FDA Approval Activities for this Drug…

Tamiflu (oseltamivir phosphate) capsules and oral suspension, Hoffman-La Roche NDA 21-087/S-010 & 21-246/S-007 4/26/02 5/2/02 4/26/02 Tamiflu (oseltamivir phosphate) capsules and oral suspension, Hoffman-La Roche NDA 21-087/S-010 & 21-246/S-007 4/9/02 4/16/02 4/9/02 Tamiflu (oseltamivir phosphate) capsules and oral suspension, Hoffman-La Roche NDA 21-087/S-009 & 21-246/S-004 11/5/01 4/22/03 Tamiflu (oseltamivir phosphate) capsules and oral suspension, Hoffman-La Roche NDA 21-087/S-008 & 21-246/S-003 07/24/01 05/08/03 Tamiflu (oseltamivir phosphate) capsules and oral suspension, Hoffman-La Roche NDA 21-087/S5/S6 07/24/01 05/08/03 Tamiflu (oseltamivir phospate) Suspension,12mg/mL [Patient Labeling] Hoffman-La Roche NDA 21-246 12/14/00 12/15/00 12/14/00 Tamiflu indication: Tamiflu is now available for oral use for the treatment of uncomplicated acute illness due to influenza in patients older than one year of age who have been symptomatic for no longer than 2 days. Tamiflu treatment significantly reduced the total composite time to freedom from illness (resolution of fever, alleviation of coryza and cough, and parental opinion of return to normal health and activity) by 1.5 days compared to placebo. Tamiflu (oseltamivir phospate) Suspension,12mg/mL Hoffman-La Roche NDA 21-246/S1 7/24/01 5/1/03 Tamiflu (oseltamivir phospate) Suspension,12mg/mL Hoffman-La Roche NDA 21-246/S3 7/24/01 5/1/03 Tamiflu (oseltamivir phospate), 75 mg capsule [Patient Labeling] Hoffman-La Roche NDA 21-087/SE1-002 11/17/00 12/15/00 12/14/00 Tamiflu (oseltamivir phospate)75 mg capsule Hoffman-La Roche NDA 21-087 Tamiflu (oseltamivir phosphate) capsules, Hoffmann-La Roche Tamiflu (oseltamivir phosphate) dry powder for suspension, Hoffmann-La Roche | TAMIFLU (oseltamivir phosphate) Capsules, Hoffmann-La Roche, Control Supplement

For the latest approval information, please see the main page.